Echo IQ Ltd (ASX:EIQ) is a Sydney-headquartered AI and medical technology company that develops software to support clinical decision-making in cardiology. Its products analyse echocardiogram data to help clinicians identify heart conditions. The company's flagship product, EchoSolv AS, is cleared by the US Food and Drug Administration (FDA) as a clinical decision support aid for detecting severe aortic stenosis, and it is pursuing clearance for EchoSolv HF, which targets heart failure. Echo IQ also has US operations based in Delaware.

On 2 October 2026, Echo IQ shares were trading at $0.58, up 1.75%. The movement took place during a firmer session for the local technology sector. As at 11:06 am, the S&P/ASX 200 Information Technology index (ASX:XIJ) was at 1,720.80, up 52.30 points or 3.13%, with tech shares tracking positive overseas momentum after earlier pressure from US bond yields eased.

Recent Developments

On 17 September 2026, Echo IQ provided an update on its application to the FDA for 510(k) clearance of EchoSolv HF. This followed an earlier announcement on 8 September 2026, in which the company disclosed that the FDA had issued a Not Substantially Equivalent (NSE) determination for its initial EchoSolv HF submission.

In the latest update, Echo IQ said it has begun work with regulatory consultants and legal counsel to address the issues cited by the FDA. Following its review of the FDA's feedback, the company said the matters raised relate to aspects of the statistical analysis supporting clinical validation, and that its assessment did not identify concerns about the underlying technology or core functionality of EchoSolv HF. Echo IQ stated that it believes there is a clear path to obtaining clearance and that this could potentially be achieved over the coming quarters.

The company outlined several possible pathways. The first is an administrative appeal of the NSE determination, which would allow it to challenge the FDA's scientific and regulatory conclusions and gain further insight into the agency's reasoning. Echo IQ noted that timelines for this process are not strictly defined and may in some circumstances be shorter than 90 days. An appeal could result in the determination being overturned, the FDA reopening its review, or the FDA requesting a resubmission with clarity on what needs to be addressed.

The second option is seeking a procedural review through the FDA Ombudsman, which can assist with reviewing the determination and supporting the company's engagement with the FDA review team. The third option is submitting a new 510(k) application, which the company said could be undertaken over the coming quarters. Echo IQ said it remains committed to working with the FDA to address all matters cited in the determination.

The company also stated that there has been no material impact on its existing strategic partner agreements, including those with Advara HeartCare, Mayo Clinic and Pro Medicus Limited. Its forward-looking statements noted that a further A$10 million Investment Tranche from Pro Medicus under a convertible note arrangement is conditional on FDA clearance of EchoSolv HF.

Echo IQ said it will keep investors and shareholders informed of progress toward obtaining clearance. The announcement was authorised for release by the company's board, with Executive Chair Andrew Grover listed as the investor contact.

Sector Context

AI-based medical software is an expanding area of healthcare technology, with tools being developed to help clinicians interpret imaging, detect disease earlier and manage high workloads. Cardiology is a key focus, as heart disease is a leading cause of illness and echocardiograms generate large amounts of data that can be analysed by algorithms.

Regulatory approval is a critical step for these products, particularly in the US, where the FDA reviews software as a medical device. The 510(k) pathway requires companies to demonstrate that their product is substantially equivalent to an existing device, and clinical validation and statistical methods are closely scrutinised. Reimbursement arrangements also play a major role in adoption, with policymakers considering how to pay for AI-enabled services.

Partnerships with established healthcare providers and imaging companies are a common route to market for AI developers, as they can provide access to clinical data, distribution channels and credibility with hospitals. Large research institutions and cardiology networks can also support validation studies, which are important both for regulatory submissions and for building clinical confidence.

Risks and Uncertainties

The key uncertainty for Echo IQ is whether, and when, EchoSolv HF will receive FDA clearance. The company itself has highlighted the risk that a revised or new submission may not succeed, or that clearance may not be obtained within any particular timeframe. Each pathway carries different timelines and outcomes, and the process could require additional time and resources.

The conditional nature of the further Pro Medicus investment tranche links part of the company's funding to the clearance outcome. As an early-stage commercial business, Echo IQ also faces risks around converting its commercial pipeline into executed contracts, the pace of clinical adoption, reimbursement decisions and competition from other AI health technology developers.

Ongoing costs associated with regulatory consultants and legal counsel may also add to expenses during this period.

Catalysts Investors Can Watch

Investors may watch for the company's decision on which regulatory pathway to pursue, whether an administrative appeal, an FDA Ombudsman review or a new 510(k) submission, as well as any subsequent FDA response. Other points of interest include updates on commercial deployments of EchoSolv AS, progress with strategic partners, developments in US reimbursement policy for AI-enabled software, and any news regarding the conditional Pro Medicus investment tranche.

The company's forward-looking statements also referenced proposed US reimbursement developments for software as a medical service, so any finalisation of these rules could be relevant to the commercial outlook for its products.

The Bottom Line

Echo IQ's September update set out its assessment of the FDA's determination on EchoSolv HF and the Options it is considering to seek clearance. Regulatory progress remains the central Factor for the company in the near term, with partner relationships reported as unaffected so far.

Any formal filing decision is likely to be the next notable milestone.